- wöchentlichErscheinungsrhythmus
- 12 mintypische Länge
- gesternletzte Folge
Oncology — a weekly podcast briefing of the most significant peer-reviewed oncology literature, synthesized from PubMed and delivered as ~10-minute audio. For practicing physicians. Generated by AudioScholar at audioscholar.cc.
Folgen
Pembrolizumab plus stereotactic RT: no EFS gain at interim
Editor's Pick: KEYNOTE-867: A Phase III, Randomized, Double-Blind Study of Stereotactic Body Radiotherapy With Pembrolizumab for Unresected Stage I or II Non-Small Cell Lung Cancer (Journal of Clinical Oncology, 2026) This AudioScholar brie
Tarlatamab plus durvalumab extends ES-SCLC survival: interim
Editor's Pick: Tarlatamab-Durvalumab Maintenance for Extensive-Stage Small-Cell Lung Cancer (New England Journal of Medicine, 2026) This AudioScholar briefing is generated by artificial intelligence for healthcare professionals and trainees
Ponatinib-blinatumomab lifts 2-year EFS to 86% in Ph+ ALL
Editor's Pick: Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL (New England Journal of Medicine, 2026) This AudioScholar briefing is generated by artificial intelligence for healthcare professionals and trainees. I
16-fraction postmastectomy RT noninferior for reconstruction
Editor's Pick: Randomized Trial of Hypofractionated Postmastectomy Radiation Therapy in Women With Breast Reconstruction (RT CHARM, Alliance A221505) (Journal of Clinical Oncology, 2026) This AudioScholar briefing is generated by artificial
Giredestrant-everolimus nearly doubles PFS in ESR1-mutant BC
Editor's Pick: Giredestrant plus Everolimus in Advanced Breast Cancer (New England Journal of Medicine, 2026) This AudioScholar briefing is generated by artificial intelligence for healthcare professionals and trainees. It is not medical ad
This Week in Oncology — Sep 30, 2026
Editor's Pick: Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer (CHN HYPOPMRT): 10-year outcomes from a randomised, non-inferiority, open-label, phase 3 trial (The Lance
DCIS margins <2 mm not tied to recurrence except age <50
Editor's Pick: Patient-Level Evaluation of Optimal Margin Width for Lumpectomy in Ductal Carcinoma In Situ: An Analysis of Patients in the National Cancer Database Special Study (Journal of Clinical Oncology, 2026) Welcome to This Week in O
Tambotatug pelitecan beats topotecan in SCLC: interim
Editor's Pick: Tambotatug Pelitecan in Small-Cell Lung Cancer after Platinum-Based Therapy (New England Journal of Medicine, 2026) Welcome to This Week in Oncology. This week we're covering 10 notable papers spanning a wave of new antibody-
Exercise and diet modestly improve QoL and fatigue on ADT
Editor's Pick: An integrated lifestyle intervention for mitigation of adverse effects associated with androgen deprivation therapy for prostate cancer (STAMINA): a multicentre, randomised trial (The Lancet Oncology, 2026) Welcome to This We
Durvalumab cuts NSCLC relapse; interim OS not significant
Editor's Pick: Perioperative Durvalumab for Resectable Non-Small Cell Lung Cancer: Updated Outcomes From the Phase III AEGEAN Trial (Journal of Clinical Oncology, 2026) Welcome to This Week in Oncology. This week we're covering 10 notable p
Prostate RT 80 vs 70 Gy with ADT: no added severe toxicity
Editor's Pick: High-dose radiotherapy in patients with high-risk prostate cancers treated with long-term androgen deprivation therapy (GETUG AFU 18): a randomised, phase 3 trial (The Lancet Oncology, 2026) Welcome to This Week in Oncology.
Adjuvant chemo: no benefit if ovarian reserve is low
Editor's Pick: Ovarian reserve as a measure of adjuvant chemotherapy benefit in hormone receptor positive, HER2-negative, node-positive breast cancer in SWOG S1007 (RxPONDER) (Annals of Oncology, 2026) Welcome to This Week in Oncology. This
Lu-PSMA-617 cuts prostate cancer progression 28%, interim
Editor's Pick: [Lu]Lu-PSMA-617 in patients with PSMA-positive metastatic androgen pathway modulator-naive/sensitive prostate cancer (PSMAddition): a phase 3 randomised, controlled trial (The Lancet, 2026) Welcome to This Week in Oncology. T
Olanzapine noninferior to dexamethasone for vomiting in kids
Editor's Pick: Dexamethasone-Free Antiemetic Prophylaxis for Children and Adolescents Receiving Highly Emetogenic Chemotherapy: A Multicenter, Phase III, Noninferiority Trial (CIVIC POD) (Journal of Clinical Oncology, 2026) Welcome to This
This Week in Oncology — Jul 31, 2026
Editor's Pick: Transarterial Chemoembolization Plus Thermal Ablation in Unresectable Hepatocellular Carcinoma: The Phase 3 TORCH Randomized Clinical Trial (JAMA Oncology, 2026) Welcome to This Week in Oncology. This week we're covering 7 no
This Week in Oncology — Jul 22, 2026
Editor's Pick: Tumor infiltrating lymphocytes as a predictor of adjuvant avelumab efficacy in patients with high-risk triple negative breast cancer (Clinical Cancer Research, 2026) Welcome to This Week in Oncology. This week we're covering
This Week in Oncology — Jul 15, 2026
Editor's Pick: Switching to camizestrant at ESR1 mutation emergence before disease progression during first-line treatment of hormone receptor-positive advanced breast cancer (SERENA-6): extended analysis of a double-blind, placebo-controll
This Week in Oncology — Jul 9, 2026
Editor's Pick: Ensartinib in Resected-Positive Non-Small-Cell Lung Cancer (The New England journal of medicine, 2026) Welcome to This Week in Oncology. This week we are covering four notable papers spanning novel therapeutic boundaries in t
This Week in Oncology — Jul 1, 2026
Editor's Pick: SBRT plus abiraterone acetate and ADT versus abiraterone acetate and ADT in oligometastatic castrate-resistant prostate cancer (ARTO): long-term, unplanned overall survival analysis of an open-label, randomised, phase 2 trial
This Week in Oncology — Jun 25, 2026
Welcome to This Week in Oncology. This week we're covering 8 notable papers spanning long-term outcomes in cellular immunotherapy, novel strategies to overcome resistance in solid tumors, and the biological drivers of early-onset cancer. Le
This Week in Oncology — Jun 18, 2026
Welcome to This Week in Oncology. This week we're covering 9 notable papers spanning major advances in multiple myeloma, the expanding role of artificial intelligence and proteomics in diagnostics, and key updates in solid tumor management.
This Week in Oncology — Jun 11, 2026
Welcome to This Week in Oncology. This week we're covering 8 notable papers spanning the rise of artificial intelligence in pathology, refinements in immunotherapy, and new insights from molecular biomarkers. Let's dive in. We begin with a
This Week in Oncology — Jun 6, 2026
Welcome to This Week in Oncology. This week we're covering 10 notable papers spanning major updates in lung cancer, novel therapeutic strategies for tough-to-treat malignancies, and new insights into tumor biology and supportive care. Let's
This Week in Oncology — May 28, 2026
Welcome to This Week in Oncology. This week we're covering 10 notable papers spanning new therapeutic strategies in solid tumors, innovations in cell therapy, and fundamental mechanisms of cancer biology. We'll also flag two key guideline u
This Week in Oncology — May 21, 2026
Welcome to This Week in Oncology. This week we're covering 10 notable papers spanning new frontiers for antibody-drug conjugates, refinements in perioperative therapy, and major updates in tough-to-treat cancers. Let's dive in. This week's
This Week in Oncology — May 14, 2026
Welcome to This Week in Oncology. This week we're covering 10 notable papers spanning major advances in treating central nervous system malignancies, new strategies for refining breast cancer therapy, and a look at emerging therapeutic plat
